Tumor-derived exosomes promote angiogenesis via adenosine A
Animals
Cell Line, Tumor
Cell Proliferation
Cellular Reprogramming
Exosomes
/ metabolism
Female
Head and Neck Neoplasms
/ metabolism
Human Umbilical Vein Endothelial Cells
/ metabolism
Humans
Macrophages
/ metabolism
Male
Models, Biological
Neovascularization, Pathologic
/ metabolism
Phenotype
Rats
Receptor, Adenosine A2B
/ metabolism
Signal Transduction
A2BR
Adenosine
Angiogenesis
Endothelial cells
Exosomes
Macrophages
TEX
Journal
Angiogenesis
ISSN: 1573-7209
Titre abrégé: Angiogenesis
Pays: Germany
ID NLM: 9814575
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
20
01
2020
accepted:
11
05
2020
pubmed:
19
5
2020
medline:
29
9
2021
entrez:
19
5
2020
Statut:
ppublish
Résumé
One hallmark of tumor-derived exosomes (TEX) is the promotion of cancer progression by stimulating angiogenesis. This study was performed to evaluate the role of adenosine receptors in TEX-induced angiogenesis. TEX produced by UMSCC47 head and neck cancer cell line were isolated by mini size exclusion chromatography (mini-SEC). Enzymatic activity of ectonucleotidases CD39/CD73 carried by TEX was measured by HPLC. Adenosine content of TEX was measured by UPLC-MS/MS. Primary human macrophages were co-incubated with TEX or exosomes derived from the plasma of head and neck cancer patients and their marker expression profile was analyzed by flow cytometry. The macrophage secretome was analyzed by angiogenesis arrays. The in vitro angiogenic potential of TEX was evaluated in endothelial growth studies. Results were validated in vivo using basement membrane extract plug assays in A TEX carried enzymatically active CD39/CD73 and adenosine. TEX promoted A This report provides the first evidence for adenosine production by TEX to promote angiogenesis via A
Identifiants
pubmed: 32419057
doi: 10.1007/s10456-020-09728-8
pii: 10.1007/s10456-020-09728-8
pmc: PMC7529853
mid: NIHMS1595431
doi:
Substances chimiques
Receptor, Adenosine A2B
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
599-610Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK068575
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL069846
Pays : United States
Organisme : NIDCR NIH HHS
ID : U01 DE029759
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK091190
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA256068
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL109002
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK079307
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA168628
Pays : United States
Références
Circ Res. 2007 Nov 26;101(11):1075-7
pubmed: 18040023
Exp Biol Med (Maywood). 2015 Nov;240(11):1472-9
pubmed: 25966978
Mol Cancer. 2014 Apr 26;13:88
pubmed: 24766647
PLoS One. 2016 Mar 10;11(3):e0151420
pubmed: 26964090
Cell Adh Migr. 2017 Mar 4;11(2):187-195
pubmed: 28129015
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Exp Cell Res. 2019 May 15;378(2):149-157
pubmed: 30857972
Blood. 2014 Dec 11;124(25):3748-57
pubmed: 25320245
Nat Cell Biol. 2008 Dec;10(12):1470-6
pubmed: 19011622
Hypertension. 2018 Aug;72(2):511-521
pubmed: 29941515
Cancer Res. 1991 Feb 15;51(4):1339-44
pubmed: 1705173
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7312-7
pubmed: 23589885
Cancer Res. 2010 Dec 1;70(23):9621-30
pubmed: 21098712
J Immunol. 2012 Jan 1;188(1):198-205
pubmed: 22116822
J Immunol. 2011 Jul 15;187(2):676-83
pubmed: 21677139
JCI Insight. 2019 Dec 5;4(23):
pubmed: 31661464
Mol Cancer Res. 2018 Nov;16(11):1798-1808
pubmed: 30042174
J Extracell Vesicles. 2018 Feb 15;7(1):1435138
pubmed: 29511460
Clin Exp Immunol. 2014 Aug;177(2):531-43
pubmed: 24749746
Adv Clin Chem. 2016;74:103-41
pubmed: 27117662
Nat Cell Biol. 2019 Feb;21(2):190-202
pubmed: 30598531
Circ Res. 2003 Mar 21;92(5):485-92
pubmed: 12600879
Cancer Res. 2018 Mar 1;78(5):1225-1240
pubmed: 29259013
J Leukoc Biol. 2015 Jan;97(1):9-18
pubmed: 25387836
Hypertension. 2002 Feb;39(2 Pt 2):530-5
pubmed: 11882603
Int J Mol Sci. 2019 Nov 14;20(22):
pubmed: 31739402
Sci Rep. 2020 Jan 9;10(1):92
pubmed: 31919420
Curr Protoc Immunol. 2019 Dec;127(1):e91
pubmed: 31763776
Clin Cancer Res. 2017 Aug 15;23(16):4843-4854
pubmed: 28400428
Am J Physiol Regul Integr Comp Physiol. 2005 Aug;289(2):R283-R296
pubmed: 16014444
Oncogene. 2013 May 30;32(22):2747-55
pubmed: 22797057
Am J Physiol. 1993 Jul;265(1 Pt 2):H131-8
pubmed: 8342624
Oncoimmunology. 2020 Apr 7;9(1):1747732
pubmed: 32313730
Expert Opin Ther Targets. 2018 May;22(5):409-417
pubmed: 29634426